As previously reported, combinatorial antibody treatments against different targets induce synergistic effects [40]; in particular, several clinical studies combining PD-L1/PD-L1 inhibitors with either ErbB2 or EGFR-TKIs in cancer patients are on-going [35,39,41]. Here, ERBB2 is linked to cancer.